Six-week oral prednisolone therapy for immune-related pneumonitis: a single-arm phase II study

BACKGROUND: There has been no prospective trial for treatment of immune-related pneumonitis (irP) occurred after immune checkpoint inhibitors (ICIs). METHODS: In this single-arm phase II study, patients with cancer with grade ≥2 irP received oral prednisolone (1 mg/kg/day), tapered over 6 weeks. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Karayama, Masato, Inui, Naoki, Inoue, Yusuke, Yasui, Hideki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Fujisawa, Tomoyuki, Enomoto, Noriyuki, Asada, Kazuhiro, Uto, Tomohiro, Fujii, Masato, Matsui, Takashi, Matsuura, Shun, Hashimoto, Dai, Toyoshima, Mikio, Ikeda, Masaki, Matsuda, Hiroyuki, Inami, Nao, Kaida, Yusuke, Funayama, Satoshi, Ichikawa, Shintaro, Goshima, Satoshi, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387737/
https://www.ncbi.nlm.nih.gov/pubmed/37500182
http://dx.doi.org/10.1136/jitc-2023-007056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387737/
https://www.ncbi.nlm.nih.gov/pubmed/37500182
http://dx.doi.org/10.1136/jitc-2023-007056

Ejemplares similares